Ramez Eskander named director of CTO at UCSD Moores Cancer Center

Combination treatment may dramatically improve survival in brain cancer

A study suggests that laser interstitial thermal therapy using NeuroBlate may enhance the effectiveness of the immunotherapy drug pembrolizumab (Keytruda) for patients with recurrent high grade astrocytoma, including glioblastoma.

March 06, 2026

Vol.52 No.09

Guest Editorial

When radiology fails to fix clinical trial imaging workflow at sites…
What most think, why it’s wrong, and what cancer centers really need

Radiology departments have tried for years to “own” or “fix” clinical trials imaging assessment workflows by extending clinical tools (PACS, worklists, dictation systems) and habits (speed, seamlessness, few clicks) into the research world.

NHS-Galleri MCD trial fails to meet primary endpoint of stage shift

High-level results from the randomized, controlled NHS-Galleri trial, which is evaluating GRAIL’s multi-cancer screening test, Galleri, over three years in 142,000 participants aged 50 to 77, reveals that the trial did not meet its primary endpoint of shifting cancer diagnosis from advanced stages (3 and 4) to earlier stage (1 and 2).

ARPA-H opens first interventional clinical trials to outpace cancer in real time

The Advanced Research Projects Agency for Health, an agency within HHS, announced the opening of the first of three adaptive oncology clinical trials, under its Advanced Analysis for Precision Cancer Therapy program.

February 20, 2026

Vol.52 No.07

Clinical Roundup

Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer

Results from the phase I/II multicenter international CADENZA trial, led by researchers at the University of Texas MD Anderson Cancer Center, show that 75% of patients with blastic plasmacytoid dendritic cell neoplasm who were treated with the antibody-drug conjugate pivekimab sunirine had a complete response.

February 20, 2026

Vol.52 No.07

Cancer Policy

“Basic Experimental Studies Involving Humans” no longer classified as clinical trials at NIH in an effort to reduce administrative burden

NIH announced Jan. 29 that “Basic Experimental Studies Involving Humans,” also called BESH, will no longer be considered clinical trials and will therefore no longer be subject to the requirements under the NIH definition of a clinical trial, including registration and reporting requirements in ClinicalTrials.gov.

February 06, 2026

Vol.52 No.05

By Jacquelyn Cobb

Ramez Eskander named director of CTO at UCSD Moores Cancer Center

YOU MAY BE INTERESTED IN

Combination treatment may dramatically improve survival in brain cancer

When radiology fails to fix clinical trial imaging workflow at sites…
What most think, why it’s wrong, and what cancer centers really need

NHS-Galleri MCD trial fails to meet primary endpoint of stage shift

ARPA-H opens first interventional clinical trials to outpace cancer in real time

Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer

“Basic Experimental Studies Involving Humans” no longer classified as clinical trials at NIH in an effort to reduce administrative burden

Renew today!

Subscriber content

Never miss an issue!

Login

Ramez Eskander named director of CTO at UCSD Moores Cancer Center

YOU MAY BE INTERESTED IN

Combination treatment may dramatically improve survival in brain cancer

When radiology fails to fix clinical trial imaging workflow at sites…What most think, why it’s wrong, and what cancer centers really need

NHS-Galleri MCD trial fails to meet primary endpoint of stage shift

ARPA-H opens first interventional clinical trials to outpace cancer in real time

Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer

“Basic Experimental Studies Involving Humans” no longer classified as clinical trials at NIH in an effort to reduce administrative burden

Never miss an issue!

Login

When radiology fails to fix clinical trial imaging workflow at sites…
What most think, why it’s wrong, and what cancer centers really need